Loading clinical trials...

Pharmacoscopy for Patients With Refractory Primary Brain Tumors | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE2

Pharmacoscopy for Patients With Refractory Primary Brain Tumors

NCT06804655•University of Zurich

Summary

Advanced technology of ex vivo drug profiling referred to as pharmacoscopy may allow to identify novel drugs for the treatment of glioblastoma and other refractory brain tumors at an individual patient level. This personalized therapeutic approach was developed and validated in pre-clinical glioma models. With the current research proposal, we seek to establish feasibility for a clinical interventional trial for patients with refractory primary brain tumors that is based on pharmacoscopy-guided selection of treatment. The study is supported by an unrestricted grant from Anti Cancer Fund.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age 18 years or older on day of signing informed consent, female or male.
•2. Refractory glioblastoma, isocitrate dehydrogenase (IDH)-mutant astrocytoma or oligodendroglioma, histone-mutant glioma, ependymoma, medulloblastoma, meningioma or other rare primary brain tumor with a histological confirmation according to the WHO classification 2021. Primary tumors can be located at the cerebral or spinal level. Primary brain tumors with metastases outside of the brain may also be considered.
•3. Karnofsky performance status of 60 or more
•4. Life expectancy \>12 weeks.
•5. Limited systemic therapeutic options as per treating physician judgement. The number of previous lines of therapies is not limited.
•6. Surgery clinically indicated. A histological confirmation of the diagnosis of a recurrent brain tumor will be required before any treatment can be initiated.
•7. Adequate bone marrow, renal and hepatic function
•8. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.
•9. Written informed consent for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.

Exclusion Criteria

•1. Inability to undergo brain or spine MRI.
•2. Concurrent treatment with other systemic tumor-directed pharmacotherapies.
•3. Intent to be treated with radiotherapy.
•4. Any investigational antitumor therapy other than those under investigation in this study.
•5. Judgment by the investigator that the patient should not participate in the study because the patient is unlikely to comply with study procedures, restrictions and requirements.
•6. Intention to become pregnant during the course of the study or pregnancy. Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test.
•7. Women who are breast feeding and who do not agree to discontinue nursing prior to the first study treatment and for the period defined in the protocol.
•8. Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.

Locations (3)

University Hospital Basel

Basel, Basel-Landschaft, Switzerland

Cantonal Hospital St Gallen

Sankt Gallen, Canton of St. Gallen, Switzerland

University Hospital Zurich

Zurich, Canton of Zurich, Switzerland

Key Dates

Start Date

February 12, 2026

Primary Completion Date

September 15, 2028

Completion Date

September 15, 2028

Last Updated

October 2, 2025

Enrollment

ESTIMATED participants

Conditions

Brain (Nervous System) CancersGlioblastomaGliomaEpendymomaMedulloblastomaMeningiomaRare Primary Brain TumorsRare CNS Primary Tumors

Interventions

Pharmacoscopy 1.0

DEVICE

Contacts

Michael Weller, Prof. Dr. med.

CONTACT

+41442555500 EViDENCE-BT@usz.ch

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant+5 more

View study

RECRUITING

Targeted Pediatric High-Grade Glioma Therapy

NCT05839379

High Grade GliomaDiffuse Intrinsic Pontine Glioma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pharmacoscopy for Patients With Refractory Primary Brain Tumors

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Targeted Pediatric High-Grade Glioma Therapy

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG